VEGFA and neoplasm: Since bevacizumab stays in the circulation for a long time, and tumor-to-background ratios remain elevated for several days, 52Mn may potentially be a more ideal candidate to use for immunoPET imaging of anti-VEGF target drug than isotopes with shorter half-lives.